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Dravet Syndrome (DS) is an encephalopathy with epilepsy associated with multiple neuropsychiatric 
comorbidities. In up to 90% of cases, it is caused by functional happloinsufficiency of the SCN1A 
gene, which encodes the alpha subunit of a voltage-dependent sodium channel (Nav1.1). Preclinical 
development of new targeted therapies requires accessible animal models which recapitulate the 
disease at the genetic and clinical levels. Here we describe that a C57BL/6 J knock-in mouse strain 
carrying a heterozygous, clinically relevant SCN1A mutation (A1783V) presents a full spectrum of DS 
manifestations. This includes 70% mortality rate during the first 8 weeks of age, reduced threshold for 
heat-induced seizures (4.7 °C lower compared with control littermates), cognitive impairment, motor 
disturbances, anxiety, hyperactive behavior and defects in the interaction with the environment. 
in contrast, sociability was relatively preserved. electrophysiological studies showed spontaneous 
interictal epileptiform discharges, which increased in a temperature-dependent manner. Seizures were 
multifocal, with different origins within and across individuals. They showed intra/inter-hemispheric 
propagation and often resulted in generalized tonic-clonic seizures. 18F-labelled flourodeoxyglucose 
positron emission tomography (FDG-PET) revealed a global increase in glucose uptake in the brain of 
Scn1aWT/A1783V mice. We conclude that the Scn1aWT/A1783V model is a robust research platform for the 
evaluation of new therapies against DS.
Dravet syndrome (DS) is a severe early onset encephalopathy (OMIM 607208) with an average incidence of 
1:20,000 births. Although it is also known as severe myoclonic epilepsy of infancy (SMEI), accounting for 1.4% 
of children with epilepsy1, seizures are not the only manifestations of the disease2. The first symptoms start at 
4–8 months of age, in a previously normal infant, as clonic or hemiclonic febrile seizures, usually prolonged and 
refractory to conventional antiepileptic drugs. The frequency of life-threatening status epilepticus (SE) in these 
patients can reach 80% during the first year of life. After this “febrile stage” of the disease, a “worsening stage” 
extends up to the fifth year of life, in which afebrile myoclonic, focal or generalized seizures are frequent, as well 
as atypical absences3. During this period a variety of neurological disturbances appear, including psychomotor 
delay leading to cognitive disability, motor disturbances as well as hyperkinesia and some features of autism 
spectrum disorder. During the “stabilization stage” these invalidating problems persist and crouching gait as well 
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as parkinsonian features appear, but epileptic episodes are less frequent. However, the risk of sudden unexpected 
death in epilepsy (SUDEP) is always present. Overall, mortality rate in DS is estimated at 15% in industrialized 
countries4, with approximately 50% of cases due to SUDEP and 35% due to SE.
In nearly 90% of DS patients, the genetic basis of the disease involves the SCN1A gene5,6, which encodes 
the alpha subunit of a voltage-dependent sodium channel (Nav1.1). This membrane transporter is crucial for 
the function of GABAergic inhibitory interneurons expressing parvalbumin or somatostatin (PV and ST cells, 
respectively)7,8. Insufficient Nav1.1 activity causes alteration in the excitatory/inhibitory balance of the brain, 
which is the basis for most clinical manifestations.
Homozygous deletions or loss of function mutations of SCN1A are extremely rare in humans, probably 
because of embryonic lethality. DS patients usually present heterozygous mutations resulting in functional inac-
tivation of one SCN1A allele9. In approximately half of the cases, the mutated allele produces a truncated Nav1.1 
channel due to nonsense, frameshift or splice defect mutations (17%, 19% and 9%, respectively)10. The other half 
presents missense mutations or in-frame deletions, with variable impact on channel function. In the lower spec-
trum of severity, missense mutations causing moderate impairment have been associated with milder diseases 
such as genetic epilepsy with febrile seizures plus (GEFS+)11. In addition, diverse functional alterations of Nav1.1 
may contribute to other neurological disorders such as autism12, familial hemiplegic migraine13, and aging-related 
cerebral impairment14.
Advances in the understanding of DS pathophysiology and the development of new therapies require relevant 
animal models. This is especially important for the evaluation of novel approaches aimed at restoring Nav1.1 
expression or function, which offer the opportunity to control not only seizures, but also the rest of invalidating 
comorbidities.
A variety of genetic mouse models based on Scn1a alterations have been described. Most of them rely on 
deletions of the gene, either globally or affecting specific cell populations. Mice harboring homozygous deletions 
in the C57BL/6 background inexorably die two weeks after birth15–17, whereas happloinsufficient mice show spon-
taneous seizures and elevated mortality from 3 to 12 weeks of age, resulting in 20% long-term survival16. In con-
trast, clinical manifestations are very mild in the 129 Sv background18. Conditional deletion of Scn1a in different 
cell populations has been obtained by crossing mice carrying one floxed Scn1a allele with those expressing Cre 
recombinase under the control of specific promoters7,19–21. The prominent role of GABAergic inhibitory interneu-
rons is in line with the drastic epileptic phenotype observed in the VGAT-Cre strain, which is more severely 
affected than the global Scn1a deficient mice. In contrast, deletion of Scn1a in excitatory neurons (Emx1-Cre 
strain) showed no epileptic phenotype19. Supporting this concept, a recent work demonstrates that 100% of mice 
carrying the Scn1a A1783V mutation in VGAT-expressing cells die before postnatal day 2522. To narrow down 
the implication of different interneuron populations, Nav1.1 was deleted in PV vs ST cells. The results showed 
that defects in ST cells caused only a mild phenotype. In contrast, mice with defects in PV cells suffered a marked 
reduction in the threshold temperature for hyperthermia-induced seizures, together with behavioral abnormali-
ties20. However, the implication of ST cells in the phenotype of DS mice has been demonstrated in other reports7. 
Apart from the specific alteration introduced in the Scn1a gene of each mouse model (deletions, frameshift or 
missense mutations), the genetic background is an important modifier factor16,18. This may explain discrepancies 
between different studies regarding the role of ST and PV cells on specific manifestations such as hyperactivity 
and autistic-like behaviors7,20. Although these tools are helping to elucidate the physiopathology of DS, preclinical 
development of new therapies requires a widely available mouse model with the ability to recapitulate the human 
disease at the genetic and phenotypic levels.
To this end, we have employed conditional knock-in mice with a heterozygous Scn1a A1783V mutation in 
all cells, maintained in a C57BL/6J background. This is a pathogenic missense mutation in exon 26, previously 
described in DS patients10,23, which is expected to affect the inactivation gate receptor of Nav1.1 located in the S6 
segment of domain 422,24. In this report we describe a remarkable reproduction of DS manifestations in all aspects 
of the disease such as epileptic activity, motor, behavioral and cognitive alterations. Of note, a knock-in model 
harboring the same mutation (B6(Cg)-Scn1atm1.1Dsf/J strain crossed with Sox2-Cre expressing mice) has been 
recently adopted by the US National Institute of Neurological disorders and Stroke (NINDS) in the panel of ani-
mal models of the Epilepsy Therapy Screening Program (ETSP). This is the first model of genetic epilepsy to be 
included in the panel (https://dravet.eu/novel-open-access-mouse-model-of-dravet-syndrome/).
Results
Scn1aWT/A1783V mice have a high mortality rate. The B6(Cg)-Scn1atm1.1Dsf/J strain contains Scn1a exon 
26 flanked by loxP sites in one of the alleles, followed by a humanized exon 26 with a C to T change at nucle-
otide 5348 (https://www.jax.org/strain/026133). Mice from the B6.C-Tg(CMV-Cre)1Cgn/J strain express Cre 
under the control of the ubiquitous CMV promoter. When these strains are crossed, the floxed exon can suffer 
Cre-mediated scission and the mutated exon 26 is incorporated in the mature mRNA expressed from this allele. 
This happens in approximately half of the offspring (genotype hereinafter referred to as Scn1aWT/A1783V). In these 
mice, 50% of the Nav1.1 channels expressed in every cell contain the A1783V amino acid change. Litters of these 
crosses showed a 24% mortality rate before weaning. In all cases analyzed, dead pups corresponded to Scn1aWT/
A1783V mice. The weight of Scn1aWT/A1783V mice surviving after weaning was lower than their Scn1aWT/WT litter-
mates until the 8th week of age (Fig. 1a). Survival of Scn1aWT/A1783V mice dropped sharply from weaning to the 6th 
weeks of age, and then it remained relatively stable, resulting in approximately 25% long-term survivors (Fig. 1b). 
Although the main cause of death in these animals needs further study, our results point to SUDEP, since the 
frequency of spontaneous generalized tonic clonic seizures (15% of mice, starting from week 3 of age) cannot 
account for the high mortality rate observed.
Analysis of Scn1a expression quantified at the mRNA level showed a moderate reduction in hippocampus of 
Scn1aWT/A1783V mice (Fig. 2a), but no significant changes in Nav1.1 content were observed in membrane-enriched 
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extracts by Western blot in any brain structure. If anything, the reduction would be less than 20% (Fig. 2b), and 
no obvious differences were detected in the immunofluorescence analysis of brain samples (Fig. 2c,d). This is 
compatible with the expected outcome of a heterozygous missense mutation.
Scn1aWT/A1783V mice present abnormal interictal activity and heat-induced seizures. In order to 
define the seizure-threshold temperature of this DS model, Scn1aWT/A1783V and their corresponding control litter-
mates were subjected to hyperthermia at different age intervals (1–2, 2–4 and 4–6 months of age). All Scn1aWT/A1783V 
mice suffered clinically recognizable seizures, with an average threshold of 38.2 ± 2.9 °C (Fig. 3a). In contrast, 80% 
of Scn1aWT/WT mice experienced seizures only when temperatures increased to a maximum of 45 °C (Fig. 3b), 
showing an average threshold of 42.9 ± 1.4 °C.
Multisite recordings (hippocampus and prefrontal cortex) were performed in a subgroup of animals from the 
1–3 age range to investigate electrophysiological differences between Scn1aWT/A1783V and Scn1aWT/WT littermates 
(Fig. 4). Thirty minutes of electrophysiological activity together with synchronized digital video recording in 
awake, freely moving mice in an open-field arena revealed the presence of interictal epileptiform discharges 
(IEDs) in all of the Scn1aWT/A1783V mice (5 out of 5) at room temperature (RT). IEDs discharges consisted in 
isolated or grouped spikes (multispike) with very short durations (<20 ms) and high amplitudes (>100 µVpp) 
standing above the background activity (Fig. 4a). Both, focal (i.e. presence of IEDs in a single channel) and gen-
eralized (presence of IEDs across several channels simultaneously) distributions were observed. Interestingly, no 
IEDs were detected in any of their Scn1aWT/WT littermates (5 out of 5). Mice’s brain activity was then recorded 
at increasing temperatures (Fig. 4a). None of the Scn1aWT/WT mice showed evidence of clinic (electrical seizures 
with behavioral manifestations) or subclinic (electrical seizures without clear behavioral manifestation) seizures 
nor the presence IEDs within the range of temperatures investigated (28–42 °C). On the contrary, Scn1aWT/A1783V 
mice showed an increase in the rate of IEDs at increasing temperatures (Fig. 4a) that ultimately led to the appear-
ance of clinical (4/5) or subclinical (1/5) heat-induced seizures in all the animals. Seizures in Scn1aWT/A1783V mice 
persisted for several minutes. Visual inspection of the simultaneous video and electrophysiological recordings 
allowed correlation between changes in the electrophysiological activity and behavioral manifestations following 
a revised Racine scale (rRS) for mice25. At RT IEDs appeared randomly superimposed on the ongoing baseline 
activity with no behavioral manifestation (no jerks, whisker trembling nor behavioral arrest). At increasing tem-
peratures, behavioral manifestation compatible with scores 0–2 of the rRS where accompanied with electrical 
activity deceleration and in some cases, increases in the rate of IEDs. When approaching to the onset, electrical 
Figure 1. Scn1aWT/A1783V mice present reduced body weight and high mortality during the first 6 weeks of 
life. (a) Animals were weighted once per week since weaning. Points represent mean values ± SEM (females 
Scn1aWT/WT average n = 30; females Scn1aWT/A1783V n = 20; males Scn1aWT/WT n = 40; males Scn1aWT/A1783V 
n = 15). Weight curves of Scn1aWT/A1783V and control littermates mice show significant differences in elevation 
(p < 0.0001) but not in slope (linear regression analysis). (b) Survival curves of mice after weaning (postnatal 
day 21) are significantly different (p < 0.0001 log-rank test). Of note, Scn1aWT/A1783V mice present a 24% 
mortality rate before weaning.
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Figure 2. Scn1aWT/A1783V mice present reduced Scn1a mRNA in hippocampus, but no significant differences 
in any brain region at the protein levels. (a) mRNA levels of Scn1a were determined by qRT-PCR in the cortex 
(Ctx), hippocampus (HC) and cerebellum (Cb) of Scn1aWT/A1783V and aged-matched littermates (5–8 months). 
Values (normalized against GAPDH mRNA levels) were calculated as percentage vs control littermates and 
data represented as mean ± SEM (n = 6 for Scn1aWT/WT mice and n = 8 for Scn1aWT/A1783V mice). *p < 0.05 
Kruskal-Wallis with Dunn’s post-test. (b) Membrane-enriched protein extracts prepared from Ctx, HC and Cb 
were used to evaluate Nav1.1 protein content by Western blotting. Bars represent the densitometric analysis of 
individual determinations normalized to GAPDH values. Data are represented as mean percentage ± SEM of 
values normalized to control mice (n = 6 for Scn1aWT/WT mice and n = 8 for Scn1aWT/A1783V mice). No statistical 
differences were found between control and Scn1aWT/A1783V mice. The right panel corresponds to representative 
blots showing Nav1.1 and GAPDH bands. Original blots were cropped and re-arranged to display grouped 
Scn1aWT/A1783V and control littermates. Full-length blots are available in supplemental material. (c) Additional 
mice were sacrificed for analysis of Nav1.1 by immunofluorescence (green). Nuclei are stained with DAPI 
(blue). The image shows the indicated brain areas: prefrontal cortex (pCtx); dentate gyrus of the HC (HC-DG); 
and Cb of representative mice (n = 4 for both groups of animals). The different regions of each structure were 
delimited by dotted lines based on the Allen adult mouse brain reference atlas. In pCtx roman numbers indicate 
its different layers. In HC-DG the following regions are included: stratum lacunosum-molecurare of CA1 
(CA1-slm); and molecular layer (GD-mo), granule cell layer (DG-sg) and polymorph layer (DG-po) of dentate 
gyrus. In Cb: molecular layer (ml), white matter (wm), purkinje cell layer (pcl) and granule layer (gl). Scale 
bar 200 µm. (d) In order to study the subcellular localization of Nav1.1 channel, tissue sections were visualized 
using a confocal laser scanning microscope. The panel shows the labelling observed in cortical later V (Ctx-LV), 
HC-DG and Cb of representative mice (n = 4 for both groups of animals). Scale bar 20 µm.
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activity became more regular (rhythmic) with slightly smaller amplitude and behavioral manifestations included 
neck jerks, head nodding and clonic tail elevation (score 3) together with falls of the animal into a sitting position 
or presence of tonic or clonic contractions in one of the legs (compatible with scores 4–5 of the rRS). Then, elec-
trical activity suddenly changed and showed intermittent clusters of high amplitude polyspikes and spike-wave 
discharges separeated by periods where EEG traces appeared almost flat (although there was still some electric 
activity). High amplitude polyspikes and spike-wave periods were accompanied by behavioral manifestations 
compatible with rRS 5 −6 (i.e clonic and tonic-clonic seizures lying on belly/side or wild jumping). Silent periods 
were accompanied by episodes of arrest with tonic extension of the muscles corresponding to the maximum score 
(7). In some cases, seizures persisted after removing the animal from the recording/heating chamber and stopped 
only when placing mice in a colder environment. In one case, the increase of temperature induced a status epilep-
ticus (SE) of generalized tonic-clonic seizures leading to death.
In two cases electrophysiological recordings allowed detection of a focal origin in the dentate gyrus of the 
hippocampus with further generalization to other areas of the hippocampus and prefrontal cortex (see Fig. 4b).
Scn1aWT/A1783V mice show cognitive impairment. Spatial learning and memory were evaluated using 
the Morris water maze (MWM) test at different age intervals (1–3, 3–5 and 5–8 months). The visible platform 
phase of the test revealed that Scn1aWT/A1783V mice learned new tasks more slowly than their control littermates, 
which is consistent with the cognitive delay observed in DS patients (Fig. 5a). The difference between both groups 
was more dramatic in terms of spatial memory, as shown in the invisible platform phase of the test. This indicates 
that Scn1aWT/A1783V mice are unable to use visual cues to accelerate the location of the hidden platform. In agree-
ment with a defect in retention, the probe test showed significant differences in all age groups.
The novel object recognition tests revealed no differences in short-term visuospatial memory (1 h after train-
ing) (NOR 1 h, Fig. 5b). However, long-term visuospatial recognition memory impairment was observed in 
Scn1aWT/A1783V mice compared to control littermates at mild and late stages of the disease (NOR 24 h, Fig. 5b), 
indicating a fail of memory consolidation in this animal model that supports the results obtained in the MWM.
Scn1aWT/A1783V mice suffer motor alterations. Gait and movement abnormalities were apparent in 
Scn1aWT/A1783V mice right after weaning. In order to quantify motor skills, mice were subjected to a battery of 
tests, including rotarod, inverted grid and elevated beam. Altogether, these tests revealed a significant impairment 
in coordination and balance, compatible with the clinical observations in DS patients (Fig. 6). In general, motor 
performance declined over time in Scn1aWT/A1783V mice, although this trend only reached statistical significance 
in the rotarod test when the early and late age groups were compared (Fig. 6a).
Scn1aWT/A1783V mice present hyperactivity and anxiety. Behavioral manifestations in DS mouse mod-
els are heavily influenced by the specific Scn1a defects and the genetic background18–20. In order to investigate 
this aspect in Scn1aWT/A1783V mice we employed the open-field test. Whereas total distance moved was not differ-
ent from their control littermates (not shown) the most dramatic difference observed was the time spent in the 
center of the arena (Fig. 7a). This is a strong indicator of anxiety behavior in these mice. In addition, Scn1aWT/
A1783V showed faster peak velocities than controls (Fig. 7b), suggesting hyperactivity/impulsivity. This result is 
Figure 3. Scn1aWT/A1783V are prone to suffer heat-induced seizures. Mice of the indicated age ranges were 
exposed to controlled hyperthermia in a chamber with 0.5 °C increments in temperature every 30 s up to 45 °C 
or until a generalized seizure was reached. (a) Thresholds were significantly lower in Scn1aWT/A1783V compared 
with their control littermates at all age ranges tested. These differences were maintained throughout all the age 
range tested (Scn1aWT/WT: 1–2 mo n = 23, 2–4 mo n = 27 and 4–6 mo n = 9; Scn1aWT/A1783V: 1–2 mo n = 26, 2–4 
mo n = 20 and 4–6 mo n = 13). ***p < 0.001, One-way ANOVA with Tukey’s post-test. (b) Cumulative seizure 
probability showing that the risk of seizures is confined between 40–45 °C in all ages in Scn1aWT/WT mice, 
whereas Scn1aWT/A1783V present a wider temperature range at young ages.
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in agreement with the behavior observed during animal handling. In support to the hyperactive behavior, we 
observed an increase in the number of repetitive movements (stereotypies), starting at 3 months of age (Fig. 7c). 
In parallel with these signs of hyperactivity, exploratory behavior was severely impaired, as revealed by the marble 
burying test. Scn1aWT/A1783V mice showed a marked reduction in the normal tendency of rodents to cover objects 
found in their cages (Fig. 7d). With the aim of studying a complex, species-adapted behavior that could evaluate 
the individual’s performance in daily life activities, we carried out the nest building test. A dramatic reduction in 
nest assembly was observed in Scn1aWT/A1783V mice, with more than 80% of individuals unable to initiate building 
at all age intervals tested (Fig. 7e). In contrast with these behavioral alterations, we could only find mild signs of 
impaired sociability when mice were subjected to the social interaction test26. Scn1aWT/A1783V mice in the interme-
diate age group showed a moderate reduction in contacts during the 15 min period of co-habitation, which was 
concomitant to an increase in the latency to first contact (Fig. 7f). Therefore, it seems that the main reason for the 
reduced number of contacts is the delay in the establishment of the first interaction, which could be influenced 
by the other motor and behavioral defects. This finding is in line with the clinical features of DS patients, whose 
social abilities are more preserved than the communication skills due to their cognitive impairment27.
Scn1aWT/A1783V mice show increased glucose uptake in the brain. It has been recently described that 
DS patients develop abnormal brain glucose uptake starting at 6 years of age28,29. In particular, reduced glucose 
uptake was reported in the fronto-temporo-parietal cortices. Although studies are still very limited, this indica-
tor of cellular metabolism could become a prognostic factor for brain function and/or a marker for therapeutic 
response in these patients. Therefore, we performed18 FDG-PET in young and middle-aged Scn1aWT/A1783V mice 
and age-matched controls that were not subjected to any thermally-induced seizure. In contrast with current 
clinical reports, we observed a global increase in glucose uptake specifically in the brain of Scn1aWT/A1783V mice. 
A net increase in brain emission was demonstrated, using the liver as a reference organ (Fig. 8a). Mice were then 
Figure 4. Electrophysiological characterization of freely moving Scn1aWT/A1783V mice. (a) Example of the 
electrical activity recorded in a Scn1aWT/WT (top) and Scn1aWT/A1783V (bottom) mouse during the thermal 
challenge. Two months-old animals (n = 5) were introduced in the heating chamber, and temperature was 
increased gradually while electrical activity was recorded in the prefrontal cortex/frontal associative cortex 
(PFC), CA1 and dentate gyrus (DG) regions. The heat source was switched on at t = 800 s. In the case of 
the Scn1aWT/A1783V mouse the seizure starts around t = 1,700 s, at T = 38.94 °C. Despite the heat source was 
immediately disconnected, seizures persisted and were organized in clusters, even when the animal was 
removed from the recording chamber (around t = 2,250 s). Note the presence of IEDs at RT (t < 1,000 s) and 
how they increase in frequency as the temperature rises, reaching a maximum right before the seizure (bottom). 
In contrast, neither IEDs nor seizures were observed in the case of the Scn1aWT/WT mouse (top). (b) Example of 
a seizure with focal origin in the DG that is further generalized (see arrow).
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Figure 5. Scn1aWT/A1783V mice show cognitive alterations involving task learning and visuospatial memory. (a) 
The MWM test performed at different ages showed increased escape latency in the visible platform (VP) in the 
Scn1aWT/A1783V mice compared with their littermate controls, although significant learning was present in both 
groups of mice (p < 0.001 Friedman test). In contrast, the performance in the invisible platform (IP) showed 
differences both in absolute latencies and the slope of curves, indicating that Scn1aWT/A1783V mice are unable to 
improve their escape latency throughout the training (p > 0.05 and p < 0.001 for Scn1aWT/A1783V and Scn1aWT/
WT mice, respectively, Friedman). In concordance with the lack of spatial learning, Scn1aWT/A1783V mice showed 
no preference for the target quadrant in the probe test, consistent with altered retention. Values are represented 
as mean ± SEM (Scn1aWT/WT: 1–3 mo n = 11, 3–5 mo n = 12 and 5–8 mo n = 27; and Scn1aWT/A1783V: 1–3 mo 
n = 17, 3–5 mo n = 10 and 5–8 mo n = 24). (b) The NOR test was applied to mice in the same age groups. 
Although no differences were observed 1 h after training (left panel), a significant reduction in long-term 
memory was noted in Scn1aWT/A1783V mice (NOR 24 h), revealing a defect in memory consolidation. Values are 
represented as mean ± SEM (Scn1aWT/WT: 1–3 mo n = 37, 3–5 mo n = 26 and 5–8 mo n = 27; Scn1aWT/A1783V: 
1–3 mo n = 28, 3–5 mo n = 30 and 5–8 mo n = 37). Statistical relevance was assessed applying one-way ANOVA 
with Tukey’s post-test for VP1–2, IP5, IP8, Probe 15 day 4, Probe 15 day 7, NOR 1 h and NOR 24 h or Kruskal-
Wallis with Dunn’s post-test for VP3–5, IP1–4, IP6–7 and Probe 15 day 9. *p < 0.05, **p < 0.01, ***p < 0.001 
for comparison of Scn1aWT/A1783V and Scn1aWT/WT mice. Symbols *, + and # correspond to the 1–3, 3–5 and 5–8 
months age ranges, respectively.
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sacrificed and different brain structures were isolated for quantification of radionuclide incorporation. Higher 
uptake was observed in all regions, including cerebellum, basal ganglia, brainstem, cortex, thalamus and hip-
pocampus (Fig. 8b). Potential reasons for the apparent discrepancy between recent clinical reports and our results 
are discussed below.
Discussion
DS is a complex encephalopathy affecting the inhibition/excitation balance in the brain, which explains the wide 
repertoire of clinical manifestations. Apart from the epileptic seizures, other comorbidities have a deep impact 
on the quality of life of the patients and their families. Therefore, addressing SUDEP, motor, cognitive and behav-
ioral alterations are clear objectives for new experimental therapies looking for patient-centered outcomes30. In 
this context, relevant pre-clinical models and robust methods to quantify response to treatments are becoming 
a priority in the field. In this report we have characterized a mouse model in which a missense Scn1a mutation 
recurrently observed in patients is present in all cells, thus mimicking a clinically relevant situation at the genetic 
level. Our results indicate that the most relevant DS manifestations are present in Scn1aWT/A1783V mice, and can 
be readily quantified using standardized tests. These include a marked sensitivity for thermally-induced seizures, 
EEG alterations, progressive motor impairment, hyperactivity and cognitive deterioration.
Behavioral alterations are probably the most variable manifestations among DS patients, and the same occurs 
in pre-clinical mouse models. Apart from the inherent difficulty to discriminate different behavior traits using 
rodent tests, there is a strong influence of the genetic background and the type of cells affected by the Scn1a alter-
ations. In the model described here, the open-field test was a robust method to quantify anxiety (time spent in 
the center of the arena). Although the high frequency of stereotypies observed in the Scn1aWT/A1783V mice could 
be considered an autistic-like behavior, we believe that in this case it is mainly a reflection of hyperactivity. This 
is in agreement with the increased velocity in the open-field and the hyper-reactivity experienced during animal 
handling. We believe the striking reduction in nest building performance observed in Scn1aWT/A1783V mice is a rel-
evant indicator of poor quality of life and a clear parameter to be considered in the evaluation of new therapies. In 
contrast, evidences for reduced sociability were not consistent, according to the interaction test. This is probably 
influenced by the C57BL/6 J genetic background, which is relatively resistant to social interaction defects20,31. In 
fact, PV-specific happloinsufficiency of Scn1a in this background showed normal social behavior20, and only the 
global introduction of a nonsense mutation (Scn1aRX/+ mice) caused alterations in sociability tests. On the other 
hand, reduced social skills in DS patients are better explained by their difficulties in communication and their 
cognitive impairment rather than by specific deficits in socialization27. In addition, the contribution of cerebellar 
alterations to an internalizing syndrome should be taken into account32,33.
In comparison with the previously described knock-in model carrying the R1648H mutation associated with 
GEFS+ (Scn1aRH+ mice)34, Scn1aWT/A1783V have in common the hyperactivity and mild social deficits, whereas the 
DS mutation causes deeper cognitive impairment, anxiety and higher mortality. Interestingly, a recent study indi-
cates that the phenotype of heterozygous Scn1aRH+ mice can be aggravated by repeated hyperthermia-induced 
crisis, resembling DS35. This finding highlights the interplay between genetic and environmental factors in disease 
progression.
Figure 6. Scn1AWT/A1783V mice show motor impairment. (a–c) Mice of the indicated age ranges were subjected 
to the rotarod, inverted grid and elevated beam tests, as indicated. The latency to fall from the rotatory rod 
was decreased in the Scn1AWT/A1783V mice compared with their control littermates, with significant differences 
observed from 3 months of age. For the other two tests, a significant reduction was observed in all age groups. 
Each bar represents the mean ± SEM of elapsed time (s) and are the mean of at least two trials (Scn1aWT/WT: 1–3 
mo n = 31/25/19, 3–5 mo n = 16/19/14 and 5–8 mo n = 24/14/26; Scn1aWT/A1783V: 1–3 mo n = 18/13/11, 3–5 mo 
n = 16/29/14 and 5–8 mo n = 25/16/31; respectively in each of the tests performed). *p < 0.05, **p < 0.01, and 
***p < 0.001. One-way ANOVA with Tukey’s post-test for (a) and Kruskal-Wallis with Dunn’s post-test for (b,c).
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Figure 7. Scn1AWT/A1783V mice show an altered interaction with the environment. Mice of the indicated age 
ranges were subjected to the open-field test and showed a reduction in the time spent in the center of the arena 
-indicative of anxiety- (a), hyperkinesia (b) and an increased number of stereotypies (c). No differences in total 
distance moved were detected in any age-range (data not shown). Other alterations of animal behavior included 
a reduction in the normal tendency to hide objects in the marble burying test (d) and a poor performance in 
the nest building test (e). The graph represents the percentage of mice that complete, initiate or fail to initiate 
the task during one night (dark, medium and light colors, respectively). In contrast, Scn1AWT/A1783V performed 
relatively well in the social interaction task (f), with a reduction in the number of contacts only observed 
in the 3–5 months age range (left Y axis), which coincided with a significantly higher latency to approach 
the unfamiliar mouse for the first time (right Y axis), compared with their control littermates. Values are 
represented as mean ± SEM (Scn1aWT/WT: 1–3 mo n = 44/44/14/26/16/16, 3–5 mo n = 31/30/13/34/6/11, and 
5–8 mo n = 29/27/17/8/17/18; Scn1aWT/A1783V: 1–3 mo n = 26/29/14/20/6/15, 3–5 mo n = 33/34/9/37/12/11 and 
5–8 mo n = 35/36/24/18/20/15; respectively in each of the test performed). *p < 0.05; ***p < 0.001, Kruskal-
Wallis with Dunn’s post-test.
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Finally, we report for the first time an FDG-PET study in a DS murine model, which could be an indirect, 
but clinically relevant marker for brain function in this disease. In contrast with the pioneering reports in DS 
patients28,29, we found an increase in glucose uptake in different brain structures. This is not surprising, taking 
into account the unbalanced excitatory activity resulting from the insufficient Scn1a function. We believe the 
apparent reduction of glucose uptake observed in the clinical studies can be influenced by the anti-epileptic drugs 
used in patients36, and by the normalization method used in these studies. Haginoya et al. took cerebellum as a 
reference28, whereas Kumar et al. used basal ganglia29. Our data indicate that both brain regions have elevated 
uptake positron emission, which complicates the interpretation of results. Brain metabolism is generally reduced 
in drug-resistant epilepsies37, especially as a result of prolonged exposure to seizures. However, hypermetabolism 
has been described in interictal periods when continuous epileptogenic activity is present38.
To conclude, we present here an “open access” DS mouse model based on a clinically relevant genetic alter-
ation, which allows the quantitative evaluation of a wide repertoire of disease manifestations. The selection of 
methods described in this report cover the most relevant parameters at the clinical, electrophysiological and 
metabolic levels. We believe this may be a useful tool to test novel therapies and to obtain meaningful data across 
different research groups.
Materials and Methods
Animals. The conditional Scn1a-A1783V mice (B6(Cg)-Scn1atm1.1Dsf/J, The Jackson Laboratory, stock 
no. 026133) were bred to mice expressing Cre recombinase under the control of the CMV promoter (B6.C-
Tg(CMV-Cre)1Cgn/J, The Jackson Laboratory, stock no. 00605439). Breeding pairs consisted of heterozygous 
male Scn1a-A1783V and homozygous female CMV-Cre mice. See https://www.jax.org/strain/026133 for details 
about allele modification and genotyping. Offspring carrying one mutated allele (genotype hereinafter referred to 
as Scn1aWT/A1783V) express the A1783V mutation in the Scn1a gene in all body tissues, mimicking what happens 
in DS. Animals were housed 4–6 per cage with free access to food and water, weighed weekly, and maintained 
in a temperature and light controlled (12 h/12 h light/dark cycle) environment. The studies were performed by 
comparing heterozygous transgenic Scn1aWT/A1783V to age-matched negative littermates Scn1aWT/WT. Breeding 
and experimental protocols were approved by the Ethical Committee of the University of Navarra (in accord with 
the Spanish Royal Decree 53/2013).
Figure 8. Scn1aWT/A1783V mice show increased glucose uptake in the brain. Mice were subjected to 18F-
FDG PET at the indicated ages. (a) Left panel correspond to maximum intensity projection PET images 
of representative mice showing brain 18F-FDG uptake. The quantification of positron emission (mean 
SUV) is represented in the right panel. (b) Mice in the 5–8 age group were sacrificed after PET, and isotope 
incorporation was quantified in a gamma counter (expressed as % of the injected dose). (1–2 mo n = 7; 5–8 mo 
n = 14). *p < 0.05; **p < 0.01. Mann Whitney U test.
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Quantitative pcR. In order to minimize the number of animals employed in this part of the study (lim-
ited to 6 Scn1aWT/WT and 8 Scn1aWT/A1783V), one brain hemisphere and half cerebellum of each animal were dis-
sected and employed to determine mRNA levels of the Scn1a gene by quantitative PCR, and the other one for the 
determination of Nav1.1 protein levels by Western blotting. After dissecting the cerebral cortex, hippocampus 
and cerebellum, the Maxwell® 16 LEV simplyRNA Cells Kit (Promega, Madison, WI, USA) was used for total 
RNA isolation following manufacture’s indications. Two micrograms of RNA were then treated with DNase I and 
retro-transcribed into cDNA using M-MLV retro-trasncriptase enzyme (Invitrogen, Thermo Fisher Scientific, 
Carlsbad, CA, USA) and random primers (Life Technologies, Thermo Fisher Scientific, Carlsbad, CA, USA). 
These procedures were performed in GeneAmp® PCR System 2400 (Applied Biosystems, Foster City, CA, USA). 
Quantitative analysis was performed by real-time PCR using iQTM SYBR® Green Supermix reagent (Bio-Rad, 
Hercules, CA, USA) in CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Mouse 
Scn1a expression levels were determined using specific primers (FP 5′ CATGTATGCTGCAGTTGATTCCA 
3′and RP 5′ AACAGGTTCAGGGTAAAGAAGG 3′)40 and mouse GAPDH was used as housekeeping gene (FP 
5′ CCAAGGTCATCCATGACAAC 3′and RP 5′ TGTCATACCAGGAAATGAGC 3′). All brain samples were 
tested in triplicate. The relative quantification was carried out using the 2−∆Ct41. Data are analysed in percentage 
vs Scn1aWT/WT mice and represented as mean ± SEM.
Preparation of membrane-enriched extracts and western blotting. The cerebral cortex and hip-
pocampus of the other hemisphere and half cerebellum were employed to obtain the membrane-enriched pro-
tein fraction (P2) as previously described42. Protein concentration was determined by Bradford assay (BioRad 
Laboratories, Hercules, CA) and part of the preparation was solubilized in denaturing conditions as described 
before43. Protein samples were mixed with 4x Urea-EDTA buffer, resolved onto SDS-polyacrylamide gels and 
transferred to PVDF membranes. The membranes were blocked with 5% BSA and 0.05% Tween-20 in TBS, 
followed by overnight incubation at 4 °C with the following primary antibodies: rabbit polyclonal anti-Nav1.1 
(Alomone Labs Cat# ASC–001, Cat# 2118S, 1:500) and rabbit moclonal (14C12) anti-GAPDH (Cell Signaling 
Technology, 1:5,000) diluted in 2,5% BSA, 0.05% Tween–20 and 0,01% azide in TBS. Immunolabeled protein 
bands were detected by using and anti-rabbit IgG HRP conjugate (GE Healthcare, Cat# NA934V, 1:10,000) and 
an enhanced chemiluminiscence system (Lumigen ECL Ultra TMA–6, Lumigen, Inc., Cat# TLA–100). Images 
were acquired with a Chemidoc system (Biorad, Hercules, CA, USA), and Image LabTM software (Biorad, 
Hercules, CA, USA) was used for quantification. The employed anti-Nav1.1 antibody is an affinity-purified 
rabbit polyclonal antisera raised against synthetic peptides corresponding to the intracellular loop between 
domains I and II of rat Nav 1.1. It has been KO validated44 and validated for Western blotting immunofluo-
rescence in several publications45–48 Data are analysed in percentage vs Scn1aWT/WT mice and represented as 
mean ± SEM.
Immunofluorescence procedures, equipment and settings. Additional animals were perfused tran-
scardially with 0.9% saline followed by 4% paraformaldehyde in phosphate buffer (PB) under xylazine/ketamine 
anesthesia. After perfusion, brains were removed and post-fixed in the same fixative solution for 12 h at 4 °C; and 
then cryopreserved in 30% sucrose solution in PB at 4 °C until they sank. Microtome sections (thickness: 30 μm) 
were cut sagitally with a freezing microtome and stored in cryopreserving solution (30% ethylene glycol, 30% 
glycerol in PB 0.1 M) at −20 °C until processed. To carry out the immunofluorescence, two free-floating tissue sec-
tions per animal were processed (n = 4 in each group). Brain sections were washed 3 times with PB at RT and then 
a blocking step was performed, followed by overnight incubation at 4 °C with the primary antibody (rabbit poly-
clonal anti-Nav1.1, Alomone Labs Cat# ASC–001, 1:500) diluted in blocking solution (2% donkey normal serum, 
0.5% Triton X–100 and 1% BSA in PB). After washing them 3 times with PB, slices were incubated with the sec-
ondary antibody (Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Alexa Fluor 488 Cat# A–21206, 1:400) 
for 2 h at RT and protected from light. To enable the visualization of nuclei, sections were incubated for 5 min with 
the DNA marker 4′,6–diamidino–2–phenylindole (DAPI, ThermoFisher Scientific Cat# D1306, 300 nM) pro-
tected from light. Finally, slices were washed twice with PB, mounted on super frost plus slides, air dried for 24 h, 
rinsed in toluene (2 × 5 min), and coverslip was placed with Immu-Mount® mounting medium (ThermoFisher 
Scientific Cat# 9990402). To ensure comparable immunostaining, sections were processed together under identi-
cal conditions. For the assessment of non-specific primary and secondary immunostaining, some sections from 
each experimental group were incubated without primary or secondary antibody, and no immunostaining was 
observed in any case. Fluorescence signals displayed in Fig. 2c were acquired with the fluorescence microscope 
Eclipse Eboom (Nikon) coupled to a super high-pressure mercury lamp (C-SHG1, Nikon, Japan) using a Plan 
Apo 10 ×/ 0.45 DIC L objective. Images were acquired with the DS-Ri2 camera (Nikon, Japan. Capture quality: 
3 × 8–bit, 4908 × 3264) and the program NIS-Elements F 4.60.00 64-bit (Nikon, Japan. Image information: 8 
bits, calibration 1,17 µm/px, and dimensions 808 × 808). The B-2A filter (excitation: 450–490 nm, DM: 505, BA: 
530) was used to detect Nav1.1–inmunostained structures and the UV-2A one (excitation: 330–380, DM: 400, 
BA: 420) for DAPI-staining. Emissions were color-coded in green and blue, respectively. Acquired fluorescence 
images were adjusted in parallel for brightness and contrast in ImageJ 1.52p (NIH, Bethesda, MD), sharpness 
was improved employing an unsharp mask filter (Radius (sigma): 1.0 px, and mask weight; 0.60). For bigger 
magnification (Fig. 2d) tissue sections were visualized using a confocal laser scanning microscope (Zeiss Axio 
Observer.Z1/7 LSM800 with Airyscan and ESID 2XGaAsP detector module) and a Plan-Apochromat 63 ×/ 1.40 
Oil DIC M27 objective. Tissue sections were excited using a 488 nm laser for detecting Nav1.1-inmunostained 
structures (emission wavelength 509 nm, detection wavelength 480–700 nm, pinhole 50 µm) and a 353 nm laser 
for DAPI-staining (emission wavelength 465 nm, detection wavelength 400–480 nm, pinhole 50 µm). Emissions 
were color-coded in green and blue, respectively. Images were acquired with the program ZEN 2 (blue edition) 
(Carl Zeiss. Dimensions: 512 × 512, 16-bit; and image size: 190.16 × 190.16 µm). Acquired fluorescence images 
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were adjusted in parallel for brightness and contrast in ImageJ 1.52p (NIH, Bethesda, MD), noise was removed 
applying a bright outlier detection filter (Radius: 0.1 px, and threshold: 90) and sharpness was improved employ-
ing an unsharp mask filter (Radius (sigma): 1.0 px, and mask weight: 0.20).
Induction of thermal seizures. In order to evaluate the epileptogenic thermal threshold in our animal 
model at different ages, a methacrylate cylinder coupled to a thermal system that gradually increased its inter-
nal temperature was used. Before introducing the animal into the cylinder, its body temperature was measured 
employing a rectal probe (RET-4, Physitemp Instruments, LLC) coupled to the TCAT-2LV controller (Physitemp 
Instruments, LLC). The environmental temperature was gradually increased to a maximum of 45 °C (0.5 °C every 
30 s) or until a generalized seizure was reached. After removing the animal from the cylinder and measuring its 
body temperature as described before, the animal was left in a cool box with free access to water to help it recover.
electrophysiological recordings. Electrophysiological phenotyping of the DS model was carried out by 
multisite recordings in 5 Scn1aWT/A1783V and 5 Scn1aWT/WT mice at 2 months of age (71 ± 18 days). Local field 
potentials (LFP) from the hippocampus CA1 region and prefrontal cortex together with simultaneous video 
recordings were obtained. To do that, mice were implanted with 5 equally spaced 50 µm tungsten wires (California 
Fine Wire, CA 93433, USA) across different layers of CA1 and dentate gyrus (DG) and a wire at prefrontal cor-
tex, frontal associative cortex (PFC). Coordinates for electrode placement were selected according to Paxinos 
and Watson atlas: (AP): −1.94 mm; (ML): 1.5 mm; (DV): −2 to −1 mm for the hippocampal bundles and (AP): 
2.58 mm; (ML): 1.5 mm; (DV): −1.5 mm for the PFC. Reference and ground screws were placed over the cere-
bellum. One week after implantation (time for recovery from surgery and inflammation, as recommended by the 
ethical committee), animals were connected to an acquisition system for electrophysiological recordings (Intan 
RHD2000 system, IntanTech). Simultaneous video recordings were used to assess behavioural state of the animals 
and the presence of (clinical) seizures. Recording session began with 30 min of awake, freely moving recordings of 
the mice within their cages at RT. Open-field recording was then followed by a thermal challenge where mice were 
placed into a heating chamber and recorded at increasing temperatures from RT up to 42 °C or the appearance 
of seizures. Custom-made routines running under Matlab (Mathworks, Natick, MA, USA) were used to convert 
electrophysiological data and temperature values from Intan format into Spike2 format (Cambridge Electronic 
Desing Limited, UK). Reviewing features of the Spike2 software were used to visually inspect the recordings in 
order to assess the presence of abnormal activities (interictal discharges), electrical seizures and temperature 
values at the onset of the seizures. Interictal epileptiform discharges (IEDs) were semi-automatically annotated 
by performing an initial detection following previously described methods49 and further validated by visual 
inspection. To do that, signals were loaded using Matlab scripts, resampled to 1,000 Hz, band-pass filtered in the 
60–80 Hz range and rectified. IED events were detected when the filtered envelope was > 3 times above baseline 
and unfiltered envelope was > 3 times above baseline. Envelope was computed by estimating the rms value within 
a 200 ms window. Then, candidate events were uploaded into the Spike2 file as a marker channel that was further 
reviewed and curated by two specialists. Video recordings were also reviewed by two different specialist to detect 
the presence of seizures and to report their semiologycal description according to a modified Racine score for 
mice25. Location of the electrodes was assessed by histological verification. To do that, animals were anaesthe-
tized (ketamine 75 mg/kg and xylacine 11 mg/kg intraperitoneal) and intracardially perfused with a solution of 
paraformaldehyde (PAF 4%), dissolved in phosphate buffer saline (PBS 0.1 M, pH 7.4). After perfusion, the brain 
was taken out and post-fixed during 24 h in PAF. Then it was passed to PBS-sacarose for at least 24 h. Brains were 
cut in coronal axis using a cryotome. Slices of 30 μm were obtained and processed to assess electrodes location. 
The slides were stained with thionine and then observed in a microscope to verify the location of the recording 
electrodes.
Behavioural assessment. Morris water maze test. The Morris water maze is a hippocampus-dependent 
learning task that serves to test the working and reference memory function. The test was carried out as described 
before with minor modifications43. The water maze consisted of a circular pool of 1,2 m diameter and 0,6 m height 
(LE820120, PanLab Harvard Apparatus) filled with water tinted with non-toxic white paint and maintained at 
20 °C. During the first part of the test, Visible Platform (VP), mice were trained to find the platform in order to 
escape from the water. During this phase, the platform was raised above the water surface and mice were trained 
for 5 consecutive days (four trials per day). In the second part of the test, Invisible Platform (IP), the platform was 
placed in the opposite quadrant and hidden bellow water level, and visible cues were placed in each of the four 
quadrants of the maze to allow spatial learning. Mice were trained for 8 consecutive days (four trials per day) to 
generate a spatial map that allows them to find the platform. In both phases, mice were placed into the maze fac-
ing toward the wall of the pool in selected locations pseudo-randomly established. Each trial was finished when 
the mouse reached the platform (escape latency) or after 60 s; when an animal was unable to find the platform, it 
was gently guided onto it. After each trial, animals remained on the platform for 15 s. On days 4th, 7th and 9th of 
the IP phase all mice were subjected to a probe trial in order to evaluate their retention. Platform was removed 
from the pool and mice allowed to swim during 60 s in the pool, measuring the time spent in the quadrant where 
the platform was placed during the IP for the first 15 s (Probe 15). All trials were recorded and analysed with the 
program WaterMaze3 (Actimetrics, Evanston, IL).
Novel object recognition test. Novel object recognition test (NOR) was conducted for the assessment of visuospa-
tial memory. A standard squared four compartment open-field box mildly illuminated was employed (LE800SC, 
PanLab Harvard Apparatus, 90 × 90 × 40 cm). All trials were recorded and exploration times for each object were 
analysed manually blindly. Before performing the test, animals were habituated to the box during 15 min, these 
data were employed to evaluate their motor spontaneous activity as it will be described later. The test consists of 
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three different stages; the first one is the habituation phase. Two identical objects were placed into the box, sym-
metrically separated from each other, and each mouse was allowed to explore them for 5 min. After a delay of 1 h 
or 24 h, the mouse was placed again in the cage and exposed for 5 min to one familiar object in the same position 
and to a novel object placed in a new location (NOR 1 h and NOR 24 h phases). All trials were video recorded and 
the total time spent exploring each object was measured manually by using a stopwatch. To avoid the presence of 
olfactory trails, the apparatus and the objects were thoroughly cleaned after each trial. The discrimination index 
(DI) was calculated as percentage following this equation: (Exploration time of the novel object/Total exploration 
time) × 100. Consequently, a ratio of 50% reflects equal exploration of the familiar and the novel object, indicat-
ing no learning retention, and ratios above 50% are indicative of visuospatial learning retention.
Rotarod test. Motor coordination, balance and physical condition were tested in a rotarod apparatus (LE8200 
Panlab, Harvard Apparatus). The day before the test, animals were trained to walk over the rotating rod for 5 min 
at a constant speed of 12 rpm. For the test, animals were positioned on a rod programmed to rotate with lineal 
increasing speed going from 4 to 40 rpm in 5 min. Animals underwent three trials with a resting time of 60 min 
between them. The time spent in the accelerating cylinder was recorded, representing the mean value. Of note, 
mice were not subjected to the rotarod test until they weighted at least 10 g, since animals with lower weights 
showed inconsistent results.
Inverted grid test. Grip strength was tested by evaluating the capability of the mouse to remain clinging to an 
inverted cage lid for 1 min. Animals underwent three trials with a resting time of 60 min between them. The time 
spent hanging from the lid was recorded, and the score was estimated by the mean value of the three trials.
Elevated beam test. In order to assess motor coordination the elevated beam test was used. The test was car-
ried out using a cylindrical, narrow and elevated footbridge. The animal must walk on it for a maximum of two 
minutes and the time of permanence was evaluated. Animals underwent two trials with a resting time of 60 min 
between them. The time spent over the footbridge was recorded, and the score was estimated by the mean value 
of both trials.
Open-field test. Motor activity was tested for 15 min in a standardized squared four-compartment open-field 
box mildly illuminated (LE800SC, PanLab Harvard Apparatus, 90 × 90 × 40 cm). Trials were video recorded and 
automatically analysed using a video tracking system (Ethovision XT 5.0, Noldus Information Technology B.V., 
Wageningen, The Netherlands). Parameters as distance moved (cm), mean speed (cm/s) and time spent in the 
central zone (15 cm apart from the walls) were measured and represented. The last value was employed to evaluate 
the presence of anxious behaviour. Of note, mice showing very low exploratory activity (less than 5% of the time 
dedicated to exploration) were excluded from the analysis, since they tend to remain in one corner of the cage 
and would introduce a bias in the evaluation of anxiety. The presence of stereotypies, indicative of anxiety and 
hyperactivity, was also evaluated by visual inspection and manually counted.
Marble burying test. Normal exploratory behaviour was assessed with the marble burying test50. Twelve glass 
marbles were put uniformly in a cage, three marbles per line, and mice were placed in the centre of each cage 
and allowed to interact with them for 30 min. After this period of time, two blind experimenters quantified the 
number of unburied marbles.
Nest building test. This test is useful for identifying abnormal behaviour in mice51. Animals were placed in a box 
provided with a piece of tightly packed cotton material (Nestlets™ Nesting Material, Ancare) and let to interact 
with it overnight. The day after, nesting index was evaluated and scored as no nest, partial nest or complete nest 
covering the mouse.
Social interaction task. In each trial, four pairs of mice were tested simultaneously in a standardized squared 
four-compartment open-field box mildly illuminated (LE800SC, PanLab Harvard Apparatus, 90 × 90 × 40 cm). 
Each mouse was introduced in a compartment occupied by a mouse that had never interacted with it (occupant 
mouse). Both animals could freely interact for 15 min. Trials were video recorded, and the number of social inter-
actions and latency time for the first contact was then manually analysed for each tested mouse.
Measurement of cerebral glucose uptake by positron emission tomography. Cerebral glucose 
metabolism, reflecting neuronal and synaptic activity, was assessed in vivo by positron emission tomography 
(PET) with the radiotracer 18– fluorodeoxyglucose (18F-FDG). Mice were fasted overnight but allowed to drink 
water ad libitum. Mice were injected with 18F-FDG dose (9,5 MBq ± 0,6 in 80–100 μL) through the tail vein and 
placed back in the cage for an uptake period of 50 min. Then, animals were anesthetized with 2% isoflurane 
in 100% O2 gas and placed prone to acquire a static 15-min study in a small animal PET tomograph (Mosaic, 
Philips). Images were reconstructed applying dead time, decay, and random and scattering corrections. For the 
ex vivo studies of radiotracer incorporation, animals were sacrificed at the end of the study by neck dislocation 
and different parts of brain were dissected. Ex vivo counting of radioactivity in the samples was performed in a 
gamma counter (Hidex Automatic Gamma Counter, Hidex Oy, Turuk, Finland) to calculate the percentage of 
injected dose (%ID). For the semi-cuantiative analysis of the in vivo PET images, studies were analyzed using the 
PMOD software (PMOD v3.2, PMOD Technologies Ltd., Adliswil, Switzerland). Images were expressed in stand-
ardized uptake value (SUV) units, using the formula SUV = [tissue activity concentration (Bq/cm3)/injected dose 
(Bq)] × body weight (g). To assess brain uptake of 18F-FDG, two spherical volumes of interest (VOIs) were drawn 
for each image including the entire brain and liver (reference organ). Then, a semiautomatic delineation tool was 
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used applying a predefined threshold of 50% of the maximum or minimum voxel value to obtain new VOIs that 
delimited the brain and liver respectively. Finally, the average SUV of the voxels within the VOIs were calculated 
(SUV mean) and a SUVmean ratio was calculated dividing brain SUVmean/ liver SUVmean (SUVmean ratio).
Statistical analysis. Data were processed for statistical analysis using the Graphpad Prism software. After 
identifying outliers by applying the Grubb’s test, data normality was assessed with the D’Agostino and Pearson 
omnibus normality test. In Fig. 1 linear regression analysis was performed to assess statistical significance. In the 
rest of figures, if data followed normality a one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
post hoc test was applied; otherwise, Mann Whitney U test or Kruskal-Wallis test followed by Dunn’s test were 
used. In the WMM, the Friedman test was applied to test intra-group improvement over trials. The significance 
level was set at p < 0.05.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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